Home | Business News | Browse by Publication | P | PR Newswire

Single-Day Famvir Treatment Found to Shorten the Duration of Recurrent Genital Herpes Outbreaks.

Article Excerpt
WASHINGTON, Dec. 18 /PRNewswire/ -- Results from a new study demonstrated that a single day of treatment with the antiviral Famvir(R) (famciclovir) stopped the progression to a full outbreak or shortened the duration of an outbreak in patients with recurrent genital herpes (RGH). With the completion of this study, Famvir is the only antiviral treatment that has demonstrated that a single day of therapy is effective in the treatment of RGH.

"Current standard of care for recurrent genital herpes is three or five days of oral antiviral therapy. In this study, it is thought that Famvir was effective in a single-day dose because it provided a full course of therapy upfront when the virus is most active," said Dr. Fred Aoki, Professor of Medicine, Medical Microbiology and Pharmacology and Therapeutics, University of Manitoba, and lead investigator in the study. "This is exciting news for physicians who treat people with genital herpes because controlling an outbreak with a single day of treatment has the potential to impact the overall management of recurrent genital herpes."

The research, presented today at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) also showed that Famvir significantly reduced the duration of RGH symptoms including the itching, pain, burning, tingling...